Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Third Dose AZ or Pfizer Vaccination in Sinovac-Primed Adults
NCT05049226Phase 2Completed
- Sponsor
- Mahidol University
- Start
- Sep 2021
- Primary completion
- Feb 2022
- Modality
- Viral Vector Vaccines, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ChAdOx1 nCoV-19 and tozinameran in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Mahidol University. Primary endpoints: Geometric Mean Titer of Anti-S IgG at Day 90, Geometric Mean Fold Rise of Anti-S IgG at Day 90 and 6 more. Started Sep 2021; status: completed.
02
Drugs
ChAdOx1 nCoV-19tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05049226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05049226.